Investor Presentaiton

BIOND BIOLOGICS Financial highlights (三) ISRAEL BIOTECH FUND FINANCING PARTNERSHIP WITH SANOFI SANOFI $21M in equity financing since launch HAREL SBIJI Bristol-Myers Squibb Insurance & Finance $125M upfront payment ⚫ In January 2021 Biond signed a licensing agreement with Sanofi for BND-22 • Terms: $125M upfront payment and over $1B in development, regulatory, and sales milestones, as well as tiered double digit royalty payments ⚫ Biond is leading the BND-22 phase 1 study for safety and tolerability as a single agent and combination. ⚫ Sanofi will continue clinical development and commercialization responsibilities thereafter Biond Biologics Corporate Presentation | May 2021 | Non-confidential 3

View entire presentation